Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation

Transplant Infectious Disease

Volumn 18, Issue 4, 2016, Pages 585-591

  Shah, S K ^a   McAnally, K J ^b   Seoane, L ^b   Lombard, G A ^a   LaPlace, S G ^b   Lick, S ^a   Dhillon, G S ^c   Valentine, V G ^a,d  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

lung transplantation; non tuberculous mycobacterium

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM ISOLATE; BLOOD CULTURE; BRONCHIOLITIS OBLITERANS; COMPARATIVE STUDY; CYTOMEGALOVIRUS; FEMALE; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM GORDONAE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK FACTOR; SURVIVAL ANALYSIS;

EID: 84981272294     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12546     Document Type: Article

References (42)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Lung and Heart-Lung Transplant Report–2011. J Heart Lung Transplant 2011; 30: 1104–1122.
2. Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153: 2010–2016.
3. Maurer JR, Tullis DE, Grossman RF, et al. Infectious complications following isolated lung transplantation. Chest 1992; 101: 1056–1059.
4. Gupta MR, Valentine VG, Walker JE Jr, et al. Clinical spectrum of gram-positive infections in lung transplantation. Transpl Infect Dis 2009; 11: 424–431.
5. Flume PA, Egan TM, Paradowski LJ, et al. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149: 1601–1607.
6. Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000; 69: 2360–2366.
7. Danziger-Isakov LA, Sweet S, Delamorena M, et al. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 2005; 24: 324–330.
8. Trulock EP, Bolman RM, Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis 1989; 140: 802–805.
9. Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11: 243–248.
10. Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002; 21: 391–394.
11. Baldi S, Rapellino M, Ruffini E, et al. Atypical mycobacteriosis in a lung transplant recipient. Eur Respir J 1997; 10: 952–954.
12. Torres F, Hodges T, Zamora MR. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant 2001; 20: 486–489.
13. Todd JL, Lakey J, Howell D, et al. Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am J Transplant 2007; 7: 1300–1303.
14. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115: 741–745.
15. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160: 1611–1616.
16. Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30: 790–798.
17. Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14: 452–460.
18. Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25: 1447–1455.
19. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update–a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745–755.
20. Frost AE. Donor criteria and evaluation. Clin Chest Med 1997; 18: 231–237.
21. Valentine VG, McFadden PM, Ochsner JL. Advances in lung transplantation. Ochsner J 1999; 1: 12–18.
22. Valentine VG, Taylor DE, Dhillon GS, et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 2002; 21: 319–326.
23. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1–15.
24. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713–716.
25. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
26. Dalovisio JR, Montenegro-James S, Kemmerly SA, et al. Comparison of the amplified Mycobacterium tuberculosis (MTB) direct test, Amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23: 1099–1106.
27. Russo MJ, Sternberg DI, Hong KN, et al. Postlung transplant survival is equivalent regardless of cytomegalovirus match status. Ann Thorac Surg 2007; 84: 1129–1134; discussion 1134–1135.
28. Bonatti H, Tabarelli W, Ruttmann E, et al. Impact of cytomegalovirus match on survival after cardiac and lung transplantation. Am Surg 2004; 70: 710–714.
29. Palmer SM, Grinnan DC, Diane Reams B, et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18: 179–185.
30. Patel N, Snyder LD, Finlen-Copeland A, Palmer SM. Is prevention the best treatment? CMV after lung transplantation. Am J Transplant 2012; 12 (3): 539–544.
31. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systemic review of recent publications. J Heart Lung Transplant 2002; 21 (2): 271–281.
32. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk factor for bronchiolitis obliterans syndrome in lung transplantation. Am J Resp Crit Care Med 2010; 181 (12): 1391–1396.
33. Weigt SS, Elashoff RM, Keane MP, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8 (7): 1512–1522.
34. Roman A, Manito N, Campistol JM, et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev 2014; 28 (2): 84–91.
35. McDevitt LM. Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am J Health Syst Pharm 2006; 63 (19 Suppl 5): S3–S9.
36. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999; 1 (Suppl 1): 8–12.
37. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185: 881–886.
38. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121: 3554–3563.
39. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176: 306–313.
40. Hill UG, Floto RA, Haworth CS. Non-tuberculous mycobacteria in cystic fibrosis. J R Soc Med 2012; 105 (Suppl 2): S14–S18.
41. Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807–812.
42. Dhillon GS, Valentine VG, Levitt J, et al. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clin Transplant 2012; 26: 105–110.